JP2014526515A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526515A5 JP2014526515A5 JP2014530888A JP2014530888A JP2014526515A5 JP 2014526515 A5 JP2014526515 A5 JP 2014526515A5 JP 2014530888 A JP2014530888 A JP 2014530888A JP 2014530888 A JP2014530888 A JP 2014530888A JP 2014526515 A5 JP2014526515 A5 JP 2014526515A5
- Authority
- JP
- Japan
- Prior art keywords
- drug conjugate
- drug
- item
- campesterol
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 58
- 229940079593 drug Drugs 0.000 claims description 56
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 13
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 13
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 13
- 239000000556 agonist Substances 0.000 claims description 13
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 13
- 235000000431 campesterol Nutrition 0.000 claims description 13
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 12
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 12
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 12
- 235000016831 stigmasterol Nutrition 0.000 claims description 12
- 229940032091 stigmasterol Drugs 0.000 claims description 12
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 12
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 11
- OSENKJZWYQXHBN-XVYZBDJZSA-N 24(S),25-epoxycholesterol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2CC1)C)C[C@@H]1OC1(C)C OSENKJZWYQXHBN-XVYZBDJZSA-N 0.000 claims description 9
- 229960005205 prednisolone Drugs 0.000 claims description 9
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 8
- 229960004436 budesonide Drugs 0.000 claims description 8
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 8
- 239000003862 glucocorticoid Substances 0.000 claims description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 5
- FAWLNURBQMTKEB-URDPEVQOSA-N 213546-53-3 Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(O)=O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(C)C FAWLNURBQMTKEB-URDPEVQOSA-N 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 3
- 229960002170 azathioprine Drugs 0.000 claims description 3
- 229940111134 coxibs Drugs 0.000 claims description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 3
- 229960000485 methotrexate Drugs 0.000 claims description 3
- 230000017128 negative regulation of NF-kappaB transcription factor activity Effects 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 3
- HZIJXNRGQFAGJR-UHFFFAOYSA-N 2-[2-(2-hydroxyethoxy)ethoxy]ethyl acetate Chemical compound CC(=O)OCCOCCOCCO HZIJXNRGQFAGJR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 4
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 4
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 4
- 102100036673 Sterol O-acyltransferase 2 Human genes 0.000 description 4
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 102100038495 Bile acid receptor Human genes 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 229940113720 aminosalicylate Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- 229960004168 balsalazide Drugs 0.000 description 2
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
- 229960000681 leflunomide Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 2
- 229960004963 mesalazine Drugs 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 108010016092 sterol O-acyltransferase 2 Proteins 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 2
- PRYIJAGAEJZDBO-ZEQHCUNVSA-N 5,6alpha-epoxy-5alpha-cholestan-3beta-ol Chemical compound C([C@]12O[C@H]1C1)[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 PRYIJAGAEJZDBO-ZEQHCUNVSA-N 0.000 description 1
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 1
- 235000004420 brassicasterol Nutrition 0.000 description 1
- WKZFQFQFYZJKPR-UHFFFAOYSA-N butanedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CCC(O)=O WKZFQFQFYZJKPR-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- -1 prednisolone stigmasterol glycerol ester Chemical class 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535661P | 2011-09-16 | 2011-09-16 | |
| US61/535,661 | 2011-09-16 | ||
| US201261675966P | 2012-07-26 | 2012-07-26 | |
| US61/675,966 | 2012-07-26 | ||
| PCT/US2012/055549 WO2013040441A1 (en) | 2011-09-16 | 2012-09-14 | Plant steroids and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016212948A Division JP2017019871A (ja) | 2011-09-16 | 2016-10-31 | 植物ステロイドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526515A JP2014526515A (ja) | 2014-10-06 |
| JP2014526515A5 true JP2014526515A5 (enExample) | 2015-10-08 |
| JP6035338B2 JP6035338B2 (ja) | 2016-11-30 |
Family
ID=47883793
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014530888A Expired - Fee Related JP6035338B2 (ja) | 2011-09-16 | 2012-09-14 | 植物ステロイドおよびその使用 |
| JP2016212948A Pending JP2017019871A (ja) | 2011-09-16 | 2016-10-31 | 植物ステロイドおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016212948A Pending JP2017019871A (ja) | 2011-09-16 | 2016-10-31 | 植物ステロイドおよびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10086082B2 (enExample) |
| EP (1) | EP2755660B1 (enExample) |
| JP (2) | JP6035338B2 (enExample) |
| KR (1) | KR20140093661A (enExample) |
| CN (2) | CN103987390A (enExample) |
| AU (1) | AU2012308332A1 (enExample) |
| BR (1) | BR112014006222A2 (enExample) |
| CA (1) | CA2848979C (enExample) |
| EA (1) | EA201490637A1 (enExample) |
| HK (1) | HK1200358A1 (enExample) |
| IL (1) | IL231541A0 (enExample) |
| IN (1) | IN2014CN02688A (enExample) |
| MX (1) | MX2014003260A (enExample) |
| PH (1) | PH12014500596A1 (enExample) |
| SG (1) | SG11201400652UA (enExample) |
| WO (1) | WO2013040441A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014138359A1 (en) | 2013-03-08 | 2014-09-12 | Allergan, Inc. | Steroid antibiotic conjugates |
| BR112015021836A2 (pt) | 2013-03-08 | 2017-07-18 | Allergan Inc | conjugados de antibióticos diretamente ligados com drogas esteroides |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| EP3166613A4 (en) | 2014-07-09 | 2018-02-21 | Duke University | Compositions and methods for the repair of myelin |
| EP3568138B1 (en) | 2017-01-13 | 2025-03-05 | Duke University | Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders |
| KR102139678B1 (ko) * | 2017-11-24 | 2020-07-31 | 전북대학교 산학협력단 | N-아세틸 또는 n-아실 아미노산을 포함하는 아토피 또는 가려움증 치료용 조성물 |
| CN110051674A (zh) * | 2018-07-26 | 2019-07-26 | 中国人民解放军空军军医大学第一附属医院 | 豆甾醇在制备治疗胃癌的药物中的用途 |
| US11129899B1 (en) * | 2021-03-25 | 2021-09-28 | S.S. Manufacturing Co., Ltd. | Methotrexate derivatives and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2946600A (en) | 1999-03-04 | 2000-09-21 | Eugene Science Inc. | Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same |
| DE60013130T2 (de) * | 1999-06-23 | 2005-01-05 | Forbes Medi-Tech Inc., Vancouver | Konjugate von ascorbinsäure und phytosterolen oder phytostanolen und ihre verwendung zur behandlung von gefässkrankheiten |
| WO2002072035A2 (en) * | 2001-03-14 | 2002-09-19 | Lipogenics, Inc. | Novel anti-inflammatory compositions and methods of use |
| WO2002089820A1 (en) * | 2001-05-09 | 2002-11-14 | Mediplex Corporation | Formulation of amphiphilic heparin derivatives for enhancing mucosal absorption |
| SE0103765D0 (sv) * | 2001-11-09 | 2001-11-09 | Astrazeneca Ab | New use |
| US20040236125A1 (en) * | 2002-09-25 | 2004-11-25 | Forbes Medi-Tech Inc. | Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation |
| WO2004095926A2 (en) | 2003-04-28 | 2004-11-11 | Monsanto Technology, Llc | Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield |
| US20050234025A1 (en) * | 2004-04-20 | 2005-10-20 | Forbes Medi-Tech Inc. | Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof |
| JP2008533157A (ja) * | 2005-03-14 | 2008-08-21 | マサチューセッツ・インスティテュート・オブ・テクノロジー | 疾患および障害の診断および処置のためのナノセル |
| EP2081949B1 (en) * | 2006-09-22 | 2014-12-10 | GE Healthcare Dharmacon, Inc. | Tripartite oligonucleotide complexes and methods for gene silencing by rna interference |
| US9637515B2 (en) * | 2006-11-06 | 2017-05-02 | Jina Pharmaceuticals, Inc. | Guggulphospholipid methods and compositions |
| US8188060B2 (en) * | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| SG183565A1 (en) * | 2010-03-02 | 2012-09-27 | Imagenetix Inc | Compositions comprising myristic acid and uses thereof |
-
2012
- 2012-09-14 MX MX2014003260A patent/MX2014003260A/es not_active Application Discontinuation
- 2012-09-14 AU AU2012308332A patent/AU2012308332A1/en not_active Abandoned
- 2012-09-14 EA EA201490637A patent/EA201490637A1/ru unknown
- 2012-09-14 CN CN201280056467.7A patent/CN103987390A/zh active Pending
- 2012-09-14 WO PCT/US2012/055549 patent/WO2013040441A1/en not_active Ceased
- 2012-09-14 IN IN2688CHN2014 patent/IN2014CN02688A/en unknown
- 2012-09-14 US US14/345,028 patent/US10086082B2/en not_active Expired - Fee Related
- 2012-09-14 EP EP12832645.1A patent/EP2755660B1/en active Active
- 2012-09-14 HK HK15101045.6A patent/HK1200358A1/xx unknown
- 2012-09-14 CA CA2848979A patent/CA2848979C/en not_active Expired - Fee Related
- 2012-09-14 JP JP2014530888A patent/JP6035338B2/ja not_active Expired - Fee Related
- 2012-09-14 KR KR1020147009670A patent/KR20140093661A/ko not_active Withdrawn
- 2012-09-14 PH PH1/2014/500596A patent/PH12014500596A1/en unknown
- 2012-09-14 SG SG11201400652UA patent/SG11201400652UA/en unknown
- 2012-09-14 BR BR112014006222A patent/BR112014006222A2/pt active Search and Examination
- 2012-09-14 CN CN201811306193.8A patent/CN109384825A/zh active Pending
-
2014
- 2014-03-16 IL IL231541A patent/IL231541A0/en unknown
-
2016
- 2016-10-31 JP JP2016212948A patent/JP2017019871A/ja active Pending
-
2018
- 2018-08-29 US US16/116,713 patent/US20190083632A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200495T1 (hr) | Sastavi za liječenje gastrointestinalne upale | |
| CA2848979C (en) | Conjugates comprising a plant steroid linked to a drug | |
| JP2006527193A5 (enExample) | ||
| NZ599401A (en) | Orally administered corticosteroid compositions | |
| JP2012176956A5 (enExample) | ||
| US20040014734A1 (en) | Farnesoid X-activated receptor agonists | |
| JP2013502442A5 (enExample) | ||
| JP2007522114A5 (enExample) | ||
| EP1294402A2 (de) | Verbindungen mit einer sulfonamidgruppe und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| JP2008509904A5 (enExample) | ||
| JP2008540482A5 (enExample) | ||
| FR2739029A1 (fr) | Nouvelle application therapeutique des composes antimineralo-corticoides | |
| JP2022523704A (ja) | 医薬組成物 | |
| US20120245552A1 (en) | Combination Therapy | |
| JP2006508951A5 (enExample) | ||
| HRP20150849T1 (hr) | Farmaceutski pripravak zasnovan na lijeku za zaštitu jetre i prebiotiku, proizvodnja i njegova uporaba | |
| JP2023540171A5 (enExample) | ||
| JP2008534533A5 (enExample) | ||
| JP2008515909A5 (enExample) | ||
| JP2006516651A5 (enExample) | ||
| JP2007524698A5 (enExample) | ||
| Adike et al. | Hydroxycut-related vanishing bile duct syndrome | |
| JP2001213778A5 (enExample) | ||
| Elias et al. | Coordinated defence and the liver | |
| HRP20200968T1 (hr) | Metoda liječenja i sastavi koji sadrže dualni pi3k delta-gama kinaza inhibitor i kortikosteroid |